Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%
Get an overview of the results from the phase 3 study, APOLLO, presented by Dr. Dimopoulos at ASH. New treatment for patients with refractory multiple myeloma.